Pyxis Oncology (PYXS)
(Delayed Data from NSDQ)
$1.08 USD
-0.02 (-1.82%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $1.08 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PYXS 1.08 -0.02(-1.82%)
Will PYXS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PYXS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PYXS
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
PYXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
Other News for PYXS
Crescent Biopharma appoints Jan Pinkas as CSO
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PYXS Stock News
Pyxis Oncology Elects New Directors at Annual Meeting
Pyxis Oncology Reports Increased Losses Amidst Ongoing R&D Investments
Promising Developments and Risk-Reward Profile Justify Buy Rating for Pyxis Oncology